An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Summary

The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).

Timeline

Start

2019-11-18

Primary completion

2032-05-31

Completion

2032-05-31

Publications

• Cree BAC, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Selmaj K, Wynn D, Mok K, Rowland C, Bodhinathan K, Sportelli P, Miskin HP, Steinman L. Five Years of Ublituximab in Multiple Sclerosis: ULTIMATE I and II Open-Label Extension Study. JAMA Neurol. 2026 Apr 1;83(4):348-358. doi: 10.1001/jamaneurol.2026.0007.

Drugs

Indications